Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$109.39 +4.0%	$105.71	$75.56 ▼ $139.13	$5.25B	0.51	630,955 shs	589,197 shs
BHVN Biohaven	$14.41 +7.0%	$14.56	$12.79 ▼ $55.70	$1.42B	0.98	2.05 million shs	2.21 million shs
CRSP CRISPR Therapeutics	$57.87 +2.2%	$52.73	$30.04 ▼ $71.13	$5.15B	1.8	3.51 million shs	6.93 million shs
NUVL Nuvalent	$78.24 +2.1%	$78.94	$55.53 ▼ $113.51	$5.50B	1.3	517,548 shs	284,968 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+3.95%	+5.94%	-2.62%	+2.02%	+28.92%
BHVN Biohaven	+7.06%	-4.47%	+1.61%	-8.86%	-63.34%
CRSP CRISPR Therapeutics	+2.24%	+2.71%	+2.56%	+59.37%	+20.00%
NUVL Nuvalent	+2.13%	+1.31%	-7.51%	+10.20%	+9.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8383 of 5 stars	4.5	3.0	4.5	2.4	4.2	0.6
BHVN Biohaven	3.2025 of 5 stars	4.5	1.0	0.0	2.2	2.5	0.6
CRSP CRISPR Therapeutics	2.9004 of 5 stars	3.3	2.0	0.0	3.2	3.3	0.6
NUVL Nuvalent	2.9361 of 5 stars	4.5	1.0	0.0	1.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	62.72% Upside
BHVN Biohaven	3.07	Buy	$53.75	273.00% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	23.73% Upside
NUVL Nuvalent	3.09	Buy	$119.60	52.86% Upside

Current Analyst Ratings Breakdown

Latest BHVN, NUVL, AXSM, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $50.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.15	N/A	N/A	$1.46 per share	74.92
BHVN Biohaven	N/A	N/A	N/A	N/A	$1.27 per share	N/A
CRSP CRISPR Therapeutics	$37.31M	141.06	N/A	N/A	$18.81 per share	3.08
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	38.79	N/A	-49.88%	-283.22%	-33.06%	N/A
BHVN Biohaven	-$846.42M	-$7.66	N/A	N/A	N/A	N/A	-270.65%	-143.70%	8/14/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	8/14/2025 (Estimated)

Latest BHVN, NUVL, AXSM, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
BHVN Biohaven	N/A	2.33	2.33
CRSP CRISPR Therapeutics	N/A	16.61	16.61
NUVL Nuvalent	N/A	13.57	13.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BHVN Biohaven	88.78%
CRSP CRISPR Therapeutics	69.20%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
BHVN Biohaven	16.00%
CRSP CRISPR Therapeutics	4.30%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
BHVN Biohaven	239	105.79 million	85.78 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable

BHVN, NUVL, AXSM, and CRSP Headlines

Recent News About These Companies

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

August 13 at 1:06 PM | prnewswire.com

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)

August 11 at 2:43 AM | marketbeat.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock

August 10, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 Shares

August 9, 2025 | insidertrades.com

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

August 7, 2025 | prnewswire.com

Nuvalent (NUVL) Projected to Post Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

Nuvalent (NUVL) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

XTX Topco Ltd Acquires New Stake in Nuvalent, Inc. (NASDAQ:NUVL)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 23,795 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 4, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Buy" by Brokerages

August 4, 2025 | americanbankingnews.com

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Buy" by Brokerages

August 4, 2025 | marketbeat.com

TD Asset Management Inc Purchases 23,412 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 3, 2025 | marketbeat.com

Nuvalent (NUVL) Gets a Buy from Goldman Sachs

July 30, 2025 | theglobeandmail.com

Victory Capital Management Inc. Has $1.88 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL)

July 30, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Sells 11,308 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

July 29, 2025 | marketbeat.com

Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC

July 25, 2025 | msn.com

Legato Capital Management LLC Has $629,000 Holdings in Nuvalent, Inc. (NASDAQ:NUVL)

July 25, 2025 | marketbeat.com

New York State Common Retirement Fund Buys 3,965 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

July 25, 2025 | marketbeat.com

Nuvalent (NASDAQ:NUVL) Given Outperform Rating at Wedbush

July 21, 2025 | marketbeat.com

Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial

July 21, 2025 | tipranks.com

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

July 21, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN, NUVL, AXSM, and CRSP Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$109.39 +4.16 (+3.95%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$107.47 -1.92 (-1.76%)

As of 08/13/2025 07:53 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Biohaven NYSE:BHVN

$14.41 +0.94 (+6.98%)

Closing price 08/13/2025 03:59 PM Eastern

Extended Trading

$14.34 -0.07 (-0.52%)

As of 05:18 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

CRISPR Therapeutics NASDAQ:CRSP

$57.87 +1.27 (+2.24%)

Closing price 08/13/2025 03:59 PM Eastern

Extended Trading

$58.68 +0.81 (+1.40%)

As of 05:22 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Nuvalent NASDAQ:NUVL

$78.24 +1.63 (+2.13%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$78.28 +0.04 (+0.04%)

As of 08/13/2025 05:33 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time